Preparing the Vitiligo Community for a New Treatment Era

In "Preparing the Vitiligo Community for a New Treatment Era," Dr. Rosmarin and Dr. Desai discuss what the dermatology community needs to prepare for this next treatment era.

Dr. Rosmarin previews an active late-stage pipeline: three oral JAK inhibitors, upadacitinib, ritlecitinib, and tofacitinib, are progressing through final Phase 3 stages, alongside zasocitinib, a selective TYK2 inhibitor, in Phase 2 proof-of-concept testing. He calls this an exciting moment for a field that badly needs systemic options, but argues the dermatology community must simultaneously develop consensus guidelines to guide appropriate use, duration, and combination strategies. Good stewardship, he says, requires the field to educate itself collectively rather than let individual practice patterns emerge unchecked as these new therapies reach patients.

Dr. Desai then addresses the practical cost conversations his practice already navigates for topical ruxolitinib, crediting favorable Texas coverage along with dedicated staff support for prior authorizations, specialty pharmacy coordination, and manufacturer rebate programs whenever compliant. Staying on-label, he stresses, matters throughout this process. He also describes broader advocacy work through his role as president of the Global Vitiligo Foundation, including engagement with Medicaid and Medicare coverage decisions and direct advocacy letters to CMS at both state and federal levels. Reporting claims data back to manufacturers and payers, he adds, helps build the evidence base that ultimately supports better coverage decisions over time.

Finally, Dr. Desai notes that payers typically require documentation that patients have tried and failed other therapies before approving newer options, making thorough staff-supported record-keeping essential to securing timely access. Between guideline development, advocacy infrastructure, and diligent documentation, the panel frames access as requiring coordinated effort well beyond simply having an approved therapy available on the market for prescribing physicians to use.

The next episode, "Toward Standardized Sequencing in Vitiligo Care," asks Dr. Lal and Jason whether treatment sequencing can ever be standardized.